Joost Mark - Biosyent Vice Development
| RX Stock | CAD 11.26 0.08 0.71% |
Executive
Joost Mark is Vice Development of Biosyent
| Address | 2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1 |
| Phone | 905 206 0013 |
| Web | https://www.biosyent.com |
Biosyent Management Efficiency
The company has return on total asset (ROA) of 0.1286 % which means that it generated a profit of $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2088 %, meaning that it created $0.2088 on every $100 dollars invested by stockholders. Biosyent's management efficiency ratios could be used to measure how well Biosyent manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.17 in 2024. Return On Capital Employed is likely to climb to 0.22 in 2024. At this time, Biosyent's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 5.9 M in 2024, whereas Other Current Assets are likely to drop slightly above 163.3 K in 2024.Similar Executives
| Found 13 records | EXECUTIVE Age | ||
| Mark Doolittle | Covalon Technologies | N/A | |
| Hamed Ghanei | Cipher Pharmaceuticals | N/A | |
| Henrique Dias | Knight Therapeutics | N/A | |
| Stephani Saverio | Knight Therapeutics | N/A | |
| Monica Percario | Knight Therapeutics | N/A | |
| Susan Emblem | Knight Therapeutics | N/A | |
| Hamed Abbasian | Covalon Technologies | N/A | |
| Ronald Hebert | Covalon Technologies | N/A | |
| Elaine Zhang | Covalon Technologies | N/A | |
| Katie Martinovich | Covalon Technologies | N/A | |
| Greg Leszczynski | Covalon Technologies | N/A | |
| Diane Gajewczyk | Cipher Pharmaceuticals | N/A | |
| Melanie Groleau | Knight Therapeutics | N/A | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 |
Biosyent Leadership Team
Elected by the shareholders, the Biosyent's board of directors comprises two types of representatives: Biosyent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biosyent. The board's role is to monitor Biosyent's management team and ensure that shareholders' interests are well served. Biosyent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biosyent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred DSouza, Advisor | ||
| Neelu Atwal, Director Resources | ||
| Ren Goehrum, CEO Chairman | ||
| Robert March, CFO, Senior Vice President - Finance | ||
| Joost Mark, Vice Development |
Biosyent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biosyent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biosyent Stock Analysis
When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.